Trial Profile

A Single Ascending Dose (SAD)/Multiple Ascending Dose (MAD) study of NM-0127 (Envelta) for Neuropathic pain

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Leucine enkephalin (Primary)
Indications Cancer pain; Neuropathic pain; Post-traumatic stress disorders
Focus Adverse reactions; First in man
Sponsors Virpax Pharmaceuticals

Most Recent Events

15 Nov 2023 According to a Virpax Pharmaceuticals media release, company is expect to submit the IND by in mid-2024 and initiate first in human trials in 2024.
05 Apr 2023 According to a Virpax Pharmaceuticals media release, company is on track to file the IND by the second quarter of 2024.
10 Feb 2022 According to a Virpax Pharmaceuticals media release, the company remains focused on the next steps so that it may submit an IND and then initiate a Phase 1 study in humans upon any potential FDA acceptance.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com